INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering.

Analogous to its effects on CD8 + T cells, INBRX-106m showed a trend of increasing CD4 + T eff proliferation as compared with controls in the tumor and LN ( figure 4B , online supplemental figure 4A-B ).

also in 53,322 other papers